Bosutinib/Bosulif latest Chinese instructions

Bosutinib, an anti-cancer drug pioneered by Wyeth Pharmaceuticals and later developed by Pfizer, is a representative of the second generationBcr-Abl inhibitor. The drug is specifically designed to treat Ph chromosome-positive chronic myelogenous leukemia by inhibiting the BCR-ABL tyrosine kinase to block the growth and spread of cancer cells. Since being approved by the US FDA in September 2012, bosutinib has been widely used around the world and has achieved remarkable therapeutic effects.

1. Scope of application

Bosutinib is indicated for usePatients with chronic Ph+ chronic myeloid leukemia (CML) aged 1 year and above, including newly diagnosed patients, patients who are resistant or intolerant to previous treatments, and adult patients in accelerated phase or blast phase who are resistant to or intolerant to previous treatments.

2. How to use

1. Adult dosage: It is recommended that newly diagnosed patients take 400 mg once a day with food; for patients with resistance or intolerance to previous treatments, the dose is increased to 500 mg.

2. Children’s dose: newly diagnosed patients: 300 mg/m² once daily; patients with drug resistance or intolerance: 400 mg/m², also taken with food.

3. Medication Tips: The tablets should be swallowed whole and avoid cutting or chewing. If you miss a dose for more than 12 hours, you do not need to take it again. You will continue to take the regular dose the next day.

2. Adverse reactions

1. Common reactions: including diarrhea, nausea and vomiting, thrombocytopenia, rash, etc.

2. Severe reactions: involving gastrointestinal toxicity, low blood cell count, lung swelling or fluid accumulation, liver toxicity, etc., which require close attention.

3. Precautions

1. Medical history notification: Patients should provide complete medical history information to the doctor.

2. Pregnancy and breastfeeding: Female patients need to take a pregnancy test before and after treatment, and should avoid pregnancy and breastfeeding during treatment.

5. Contraindications

It is contraindicated in those allergic to bosutinib ingredients.

6. Drug interactions

It interacts with strong and moderate CYP3A inhibitors or inducers, proton pump inhibitors, etc. It is necessary to avoid simultaneous use or adjust the medication time. For details, please consult a doctor and use it under the guidance of a doctor.

7. Medication for Special Populations

Pregnant women, lactating women, the elderly and patients with liver and kidney dysfunction should follow doctor's advice.

8. Version and Purchase

There are multiple versions of Bosutinib, including the original drug and a generic drug produced by IndiaMylan. Patients can choose according to their economic situation, but they must ensure that they purchase through formal channels to ensure drug quality and safety.

The above content is for reference only. Please strictly follow the doctor's instructions for specific use and read the drug instructions carefully. If you have any questions, please consult a professional doctor in time.